Paradigm (ASX:PAR) reports: 65% pain reduction in osteoarthritis patients treated under the US FDA expanded access program. The program treated 10 retired NFL players.
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.
